Literature DB >> 15289327

Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia.

Yoo Hong Min1, June-Won Cheong, Ji Yeon Kim, Ju In Eom, Seung Tae Lee, Jee Sook Hahn, Yun Woong Ko, Mark Hong Lee.   

Abstract

Cyclin-dependent kinase inhibitor p27Kip1 functions at the nuclear level by binding to cyclin E/cyclin-dependent kinase-2. It was shown that Akt or protein kinase B (Akt/PKB)-dependent phosphorylation of p27Kip1 led to the cytoplasmic mislocalization of p27Kip1, suggesting the potential abrogation of its activity. Here, we evaluated the localization of p27Kip1 protein in leukemic blasts in relation to Akt/PKB phosphorylation and clinical outcomes in acute myelogenous leukemia (AML). Western blot analysis of the nuclear and cytoplasmic fractions revealed a heterogenous localization pattern of p27Kip1 in AML. Cytoplasmic mislocalization of p27Kip1 was significantly associated with the constitutive serine(473) Akt/PKB phosphorylation in AML cells (P < 0.05). Transfection of U937 cells with an expression construct encoding the constitutively active form of Akt/PKB resulted in a remarkable increase in the levels of cytoplasmic p27Kip1. Whereas the transfection of U937 cells with a construct encoding dominant-negative Akt/PKB resulted in a recovery of nuclear localization of p27Kip1. Both the disease-free survival and overall survival are significantly shorter in AML cases with high cytoplasmic to nuclear ratio of p27Kip1 localization compared with the cases with low cytoplasmic to nuclear ratio (P = 0.0353, P = 0.0023, respectively). Multivariate analysis indicated that the cytoplasmic to nuclear ratio of p27Kip1 localization was an independent prognostic variable for both disease-free survival and overall survival (P = 0.043, P = 0.008, respectively). These findings additionally extend our understanding of the role of p27Kip1 in AML, and buttress the case of p27Kip1 mislocalization as a prognostic indicator and Akt/PKB/p27Kip1 pathway as a ready target for antileukemia therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289327     DOI: 10.1158/0008-5472.CAN-04-0174

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.

Authors:  Xinping Yang; Suiyang Liu; Surender Kharbanda; Richard M Stone
Journal:  Leuk Res       Date:  2011-12-03       Impact factor: 3.156

2.  Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Authors:  Deepa Sampath; Asifa Malik; William Plunkett; Billie Nowak; Betsy Williams; Michelle Burton; Srdan Verstovsek; Stefan Faderl; Guillermo Garcia-Manero; Alan F List; Said Sebti; Hagop M Kantarjian; Farhad Ravandi; Jeffrey E Lancet
Journal:  Leuk Res       Date:  2013-08-06       Impact factor: 3.156

Review 3.  Controlling protein compartmentalization to overcome disease.

Authors:  James R Davis; Mudit Kakar; Carol S Lim
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

4.  RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.

Authors:  Michelle D Larrea; Feng Hong; Seth A Wander; Thiago G da Silva; David Helfman; Deborah Lannigan; Jeffrey A Smith; Joyce M Slingerland
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

5.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

6.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

7.  p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma.

Authors:  Yiting Li; Manjula Nakka; Aaron J Kelly; Ching C Lau; Mark Krailo; Donald A Barkauskas; John M Hicks; Tsz-Kwong Man
Journal:  Cancer Res       Date:  2016-04-19       Impact factor: 12.701

8.  Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.

Authors:  Anwaar Ahmad; Jacqueline H Enzlin; Nikhil R Bhagwat; Nils Wijgers; Anja Raams; Esther Appledoorn; Arjan F Theil; Jan H J Hoeijmakers; Wim Vermeulen; Nicolaas G J Jaspers; Orlando D Schärer; Laura J Niedernhofer
Journal:  PLoS Genet       Date:  2010-03-05       Impact factor: 5.917

9.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Authors:  Ivana Gojo; Alexander Perl; Selina Luger; Maria R Baer; Kelly J Norsworthy; Kenneth S Bauer; Michael Tidwell; Stephanie Fleckinger; Martin Carroll; Edward A Sausville
Journal:  Invest New Drugs       Date:  2013-02-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.